Pulse Biosciences (PLSE) Stock Price, News & Analysis

Company Overview

Pulse Biosciences, Inc. is a medical technology company developing bioelectric therapies based on its proprietary Nano-Pulse Stimulation (NPS) technology. The platform delivers short, nonthermal electrical pulses that temporarily affect cell membranes and are designed to selectively target unwanted cells while preserving surrounding tissue.

The company’s lead commercial product is the CellFX System, a dermatology platform designed to treat certain benign skin lesions and other dermatologic conditions using NPS technology. Pulse Biosciences is also advancing applications in areas including cardiac surgery, cardiac ablation and oncology, although several of these programs remain investigational and subject to regulatory review.

Founded in 2009 and headquartered in Hayward, California, Pulse Biosciences serves the medical technology and healthcare markets primarily through its development of physician-focused systems and disposable treatment accessories. The company is led by President and Chief Executive Officer Burke T. Barrett. Its products and development programs are directed toward clinicians and healthcare providers in the United States and other international markets where applicable regulatory clearances have been obtained.

Key Stats

• Today's Range: $43.32 to $46.67
• 50-Day Range: $41.51 to $55.20
• 52-Week Range: $12.56 to $58.90
• Volume: 156,416 shs
• Average Volume: 390,779 shs
• Market Capitalization: $3.13 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $60.20
• Consensus Rating: Moderate Buy

Pulse Biosciences Stock Analysis - MarketRank™

Pulse Biosciences scored higher than 61% of companies evaluated by MarketBeat, and ranked 375th out of 870 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Pulse Biosciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.86, and is based on 1 strong buy rating, 5 buy ratings, no hold ratings, and 1 sell rating.

Upside Potential

Pulse Biosciences has a consensus price target of $60.20, representing about 36.2% upside from its current price of $44.19.

Amount of Analyst Coverage

Pulse Biosciences has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Pulse Biosciences are expected to decrease in the coming year, from ($1.34) to ($1.41) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Pulse Biosciences is -37.15, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Pulse Biosciences is -37.15, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Pulse Biosciences has a P/B Ratio of 37.13. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

17.99% of the float of Pulse Biosciences has been sold short.

Short Interest Ratio / Days to Cover

Pulse Biosciences has a short interest ratio ("days to cover") of 5.61.

Change versus previous month

Short interest in Pulse Biosciences has recently increased by 5.50%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Pulse Biosciences does not currently pay a dividend.

Dividend Growth

Pulse Biosciences does not have a long track record of dividend growth.

News and Social Media

• Score: 2.1 / 5
• News Sentiment: 0.29

News Sentiment

Pulse Biosciences has a news sentiment score of 0.29. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.74 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 8 news articles for Pulse Biosciences this week, compared to 3 articles on an average week.

Search Interest

Only 7 people have searched for PLSE on MarketBeat in the last 30 days. This is a decrease of -30% compared to the previous 30 days.

MarketBeat Follows

Only 1 people have added Pulse Biosciences to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 3.6 / 5
• Insider Trading: Acquiring Shares

Net Insider Buying

Over the last three months, insiders have purchased a net $199,931.00 in company stock, which represents 0.0064% of the company's market cap.

Insider Buying vs. Insider Selling

In the past three months, Pulse Biosciences insiders have bought more of their company's stock than they have sold. Specifically, they have bought $199,931.00 in company stock and sold $0.00 in company stock.

Percentage Held by Insiders

74.00% of the stock of Pulse Biosciences is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

76.95% of the stock of Pulse Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/06/2026
• Today: 10/16/2026
• Next Earnings (Estimated): 11/04/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Healthcare Equipment & Supplies
• Sub-Industry: Healthcare Equipment
• Current Symbol: NASDAQ:PLSE
• CIK: 1625101
• Web: www.pulsebiosciences.com
• Phone: (510) 906-4600
• Fax: N/A
• Employees: 116
• Year Founded: 2014

Price Target and Rating

• Average Price Target for Pulse Biosciences: $60.20
• High Price Target: $70.00
• Low Price Target: $55.00
• Potential Upside/Downside: +35.3%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.86
• Research Coverage: 7 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.18)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$72.78 million
• Net Margins: -6,755.78%
• Pretax Margin: -6,755.78%
• Return on Equity: -94.42%
• Return on Assets: -79.96%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 9.63
• Quick Ratio: 9.61

Sales & Book Value

• Annual Sales: $350 thousand
• Price / Sales: 8,997.87
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.19 per share
• Price / Book: 37.38

Miscellaneous

• Outstanding Shares: 70,800,000
• Free Float: 18,408,000
• Market Cap: $3.15 billion
• Optionable: Optionable
• Beta: 1.57